1-13 of 13
Leif W. Ellisen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P2-01-17: Genomic predictors of response among patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) receiving the AKT inhibitor (AKTi) ipatasertib combined w/ endocrine therapy & a CDK4/6 inhibitor (CDK4/6i) in TAKTIC trial

Free
Maxwell Lloyd, Geoffrey G. Fell, Elizabeth Scott, Jennifer C. Keenan, Laura M. Spring, Jennifer Shin, Steven J. Isakoff, Lianne Ryan, Sarah Padden, Elizabeth Fisher, Amber Newton, Beverly Moy, Andreas Varkaris, Leif W. Ellisen, Douglas S. Micalizzi, Daniel Haber, Dejan Juric, Aditya Bardia, Seth A. Wander
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-01-17.
https://doi.org/10.1158/1557-3265.SABCS24-P2-01-17
Published: 13 June 2025
View article titled, Abstract P2-01-17: Genomic predictors of response among patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) receiving the AKT inhibitor (AKTi) ipatasertib combined w/ endocrine therapy & a CDK4/6 inhibitor (CDK4/6i) in TAKTIC trial
Journal Articles

Abstract P3-10-10: Sequencing PIK3CA and AKT Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Retrospective Analysis

Free
Rachel Abelman, Amanda Jung, Laura M. Spring, Geoffrey Fell, Neelima Vidula, Arielle Medford, Janice Kim, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, Dejan Juric, Aditya Bardia, Andreas Varkaris, Seth A. Wander
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-10-10.
https://doi.org/10.1158/1557-3265.SABCS24-P3-10-10
Published: 13 June 2025
View article titled, Abstract P3-10-10: Sequencing PIK3CA and AKT Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Retrospective Analysis
Journal Articles

Abstract P3-04-06: Genomic and transcriptomic profiling of BRCA mutation carrier tissues reveals the landscape of early pathogenesis of BRCA1/2-associated breast cancer

Free
Zuen Ren, Siang Boon Koh, Kai Stewart, Nick Haradhvala, Aylin S. Dedeoglu, Isabella Vianna, Ilze Smidt, Akiko Suzuki, Taisha Joseph, Veerle Bossuyt, Esther Rheinbay, Michael Lawrence, Gad Getz, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-04-06.
https://doi.org/10.1158/1557-3265.SABCS24-P3-04-06
Published: 13 June 2025
View article titled, Abstract P3-04-06: Genomic and transcriptomic profiling of BRCA mutation carrier tissues reveals the landscape of early pathogenesis of BRCA1/2-associated breast cancer
Journal Articles

TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer

Open Access
Rachel O. Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden, Annika Putur, Elena Bitman, Win Thant, Ting Liu, Caroline Weipert, Geoffrey Fell, Laura M. Spring, Seth A. Wander, Beverly Moy, Neelima Vidula, Steven J. Isakoff, Andreas Varkaris, Dejan Juric, Ryan B. Corcoran, Leif W. Ellisen, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (10): 1966–1974.
https://doi.org/10.1158/1078-0432.CCR-24-2771
Published: 15 May 2025
View article titled, TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer
Open the PDF for TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer

Open Access
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T. Coates, Bogang Wu, Rachel O. Abelman, Laura Spring, Beverly Moy, Phoebe Ryan, Mark N. Melkonyan, Ann Partridge, Dejan Juric, Jeffrey Peppercorn, Heather Parsons, Seth A. Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven J. Isakoff, Sara M. Tolaney, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2917–2924.
https://doi.org/10.1158/1078-0432.CCR-24-0428
Published: 15 July 2024
View article titled, Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer
Open the PDF for Antibody–Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

Open Access
Siang-Boon Koh, Kenneth Ross, Steven J. Isakoff, Nsan Melkonjan, Lei He, Karina J. Matissek, Andrew Schultz, Erica L. Mayer, Tiffany A. Traina, Lisa A. Carey, Hope S. Rugo, Minetta C. Liu, Vered Stearns, Adam Langenbucher, Srinivas Vinod Saladi, Sridhar Ramaswamy, Michael S. Lawrence, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4883–4897.
https://doi.org/10.1158/1078-0432.CCR-21-0714
Published: 01 September 2021
View article titled, RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Open the PDF for RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer

Available to Purchase
Neelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, Megan Yuen, Jochen Lennerz, A. John Iafrate, Seth A. Wander, Laura Spring, Dejan Juric, Steven Isakoff, Jerry Younger, Beverly Moy, Leif W. Ellisen, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3404–3413.
https://doi.org/10.1158/1078-0432.CCR-20-3444
Published: 15 June 2021
View article titled, Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Open the PDF for Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer

Available to Purchase
Neelima Vidula, Taronish Dubash, Michael S. Lawrence, Antoine Simoneau, Andrzej Niemierko, Erica Blouch, Becky Nagy, Whijae Roh, Brian Chirn, Brittany A. Reeves, Giuliana Malvarosa, Jochen Lennerz, Steven J. Isakoff, Dejan Juric, Douglas Micalizzi, Seth Wander, Laura Spring, Beverly Moy, Kristen Shannon, Jerry Younger, Richard Lanman, Mehmet Toner, A. John Iafrate, Gad Getz, Lee Zou, Leif W. Ellisen, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4852–4862.
https://doi.org/10.1158/1078-0432.CCR-20-0638
Published: 15 September 2020
View article titled, Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Open the PDF for Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Free
Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6443–6451.
https://doi.org/10.1158/1078-0432.CCR-19-0138
Published: 01 November 2019
View article titled, FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer
Open the PDF for FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B26: A requirement for p63 function in squamous cell carcinoma in vivo: Can the pathway be targeted for therapy?

Free
Matthew R. Ramsey, Catherine Wilson, William C. Faquin, Alea A. Mills, Leif W. Ellisen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): B26.
https://doi.org/10.1158/1078-0432.TCMUSA10-B26
Published: 02 February 2016
View article titled, Abstract B26: A requirement for p63 function in squamous cell carcinoma in vivo: Can the pathway be targeted for therapy?
Journal Articles

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

Free
Hiroaki Wakimoto, Shota Tanaka, William T. Curry, Franziska Loebel, Dan Zhao, Kensuke Tateishi, Juxiang Chen, Lindsay K. Klofas, Nina Lelic, James C. Kim, Dora Dias-Santagata, Leif W. Ellisen, Darrell R. Borger, Sarah-Maria Fendt, Matthew G. Vander Heiden, Tracy T. Batchelor, A. John Iafrate, Daniel P. Cahill, Andrew S. Chi
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2898–2909.
https://doi.org/10.1158/1078-0432.CCR-13-3052
Published: 29 May 2014
View article titled, Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
Open the PDF for Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas in another window
Includes: Supplementary data
Journal Articles

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Free
Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, Andrew X. Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1884–1890.
https://doi.org/10.1158/1078-0432.CCR-13-2649
Published: 31 March 2014
View article titled, Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Open the PDF for Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma

Free
William A. Michaud, Anthony C. Nichols, Edmund A. Mroz, William C. Faquin, John R. Clark, Shahnaz Begum, William H. Westra, Hiroshi Wada, Paul M. Busse, Leif W. Ellisen, James W. Rocco
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (5): 1645–1654.
https://doi.org/10.1158/1078-0432.CCR-08-2581
Published: 27 February 2009
View article titled, Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma
Open the PDF for Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma in another window
Includes: Supplementary data